Cipla signs and symptoms licence settlement with Novartis AG

Cipla signs and symptoms licence settlement with Novartis AG

by admin- Monday, April 10th, 2023 03:33:46 PM

 

Cipla signs licence agreement with Novartis AG to manufacture & market type-2 diabetes drug- Galvus from January 1, 2026. The settlement with Novartis is problem to satisfaction of positive situations precedent.

News Updates